258 related articles for article (PubMed ID: 27927042)
1. Pharmacological treatments for methamphetamine addiction: current status and future directions.
Ballester J; Valentine G; Sofuoglu M
Expert Rev Clin Pharmacol; 2017 Mar; 10(3):305-314. PubMed ID: 27927042
[TBL] [Abstract][Full Text] [Related]
2. Pharmacotherapeutic strategies for methamphetamine use disorder: mind the subgroups.
Soares E; Pereira FC
Expert Opin Pharmacother; 2019 Dec; 20(18):2273-2293. PubMed ID: 31671001
[No Abstract] [Full Text] [Related]
3. Pharmacotherapeutic agents in the treatment of methamphetamine dependence.
Morley KC; Cornish JL; Faingold A; Wood K; Haber PS
Expert Opin Investig Drugs; 2017 May; 26(5):563-578. PubMed ID: 28351169
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological Treatment of Methamphetamine/Amphetamine Dependence: A Systematic Review.
Siefried KJ; Acheson LS; Lintzeris N; Ezard N
CNS Drugs; 2020 Apr; 34(4):337-365. PubMed ID: 32185696
[TBL] [Abstract][Full Text] [Related]
5. Current and Emerging Treatments for Methamphetamine Use Disorder.
Moszczynska A
Curr Neuropharmacol; 2021; 19(12):2077-2091. PubMed ID: 34344291
[TBL] [Abstract][Full Text] [Related]
6. A commentary on the effects of methamphetamine and the status of methamphetamine abuse among youths in South Korea, Japan, and China.
Kwon NJ; Han E
Forensic Sci Int; 2018 May; 286():81-85. PubMed ID: 29567545
[TBL] [Abstract][Full Text] [Related]
7. Treatments for methamphetamine abuse: a literature review for the clinician.
Brackins T; Brahm NC; Kissack JC
J Pharm Pract; 2011 Dec; 24(6):541-50. PubMed ID: 22095579
[TBL] [Abstract][Full Text] [Related]
8. Pharmacotherapy of amphetamine-type stimulant dependence: an update.
Brensilver M; Heinzerling KG; Shoptaw S
Drug Alcohol Rev; 2013 Sep; 32(5):449-60. PubMed ID: 23617468
[TBL] [Abstract][Full Text] [Related]
9. Quite a lot of smoke but very limited fire--the use of methamphetamine in Europe.
Griffiths P; Mravcik V; Lopez D; Klempova D
Drug Alcohol Rev; 2008 May; 27(3):236-42. PubMed ID: 18368604
[TBL] [Abstract][Full Text] [Related]
10. Oxytocin-enhanced motivational interviewing group therapy for methamphetamine use disorder in men who have sex with men: study protocol for a randomized controlled trial.
Stauffer CS; Moschetto JM; McKernan SM; Hsiang E; Borsari B; Woolley JD
Trials; 2019 Feb; 20(1):145. PubMed ID: 30791944
[TBL] [Abstract][Full Text] [Related]
11. On the necessity of translational cognitive-neurotoxicological research in methamphetamine abuse and addiction.
Stock AK; Beste C
Arch Toxicol; 2017 Jul; 91(7):2707-2709. PubMed ID: 28444486
[No Abstract] [Full Text] [Related]
12. Trace amine-associated receptor 1: A promising target for the treatment of psychostimulant addiction.
Jing L; Li JX
Eur J Pharmacol; 2015 Aug; 761():345-52. PubMed ID: 26092759
[TBL] [Abstract][Full Text] [Related]
13. Cognitive Deficits in Methamphetamine Users: How Strong is The Evidence?
Proebstl L; Kamp F; Koller G; Soyka M
Pharmacopsychiatry; 2018 Nov; 51(6):243-250. PubMed ID: 29334687
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of psychostimulants for amphetamine and methamphetamine use disorders: a systematic review and meta-analysis.
Bhatt M; Zielinski L; Baker-Beal L; Bhatnagar N; Mouravska N; Laplante P; Worster A; Thabane L; Samaan Z
Syst Rev; 2016 Nov; 5(1):189. PubMed ID: 27842569
[TBL] [Abstract][Full Text] [Related]
15. Methamphetamine: an update on epidemiology, pharmacology, clinical phenomenology, and treatment literature.
Courtney KE; Ray LA
Drug Alcohol Depend; 2014 Oct; 143():11-21. PubMed ID: 25176528
[TBL] [Abstract][Full Text] [Related]
16. Transcriptome profiling and pathway analysis of genes expressed differentially in participants with or without a positive response to topiramate treatment for methamphetamine addiction.
Li MD; Wang J; Niu T; Ma JZ; Seneviratne C; Ait-Daoud N; Saadvandi J; Morris R; Weiss D; Campbell J; Haning W; Mawhinney DJ; Weis D; McCann M; Stock C; Kahn R; Iturriaga E; Yu E; Elkashef A; Johnson BA
BMC Med Genomics; 2014 Dec; 7():65. PubMed ID: 25495887
[TBL] [Abstract][Full Text] [Related]
17. Why do we need an Addiction supplement focused on methamphetamine?
Rawson RA; Condon TP
Addiction; 2007 Apr; 102 Suppl 1():1-4. PubMed ID: 17493048
[TBL] [Abstract][Full Text] [Related]
18. The NIDA Methamphetamine Clinical Trials Group: a strategy to increase clinical trials research capacity.
Elkashef A; Rawson RA; Smith E; Pearce V; Flammino F; Campbell J; Donovick R; Gorodetzky C; Haning W; Mawhinney J; McCann M; Weis D; Williams L; Ling W; Vocci F
Addiction; 2007 Apr; 102 Suppl 1():107-13. PubMed ID: 17493059
[TBL] [Abstract][Full Text] [Related]
19. Could sigma receptor ligands be a treatment for methamphetamine addiction?
Rodvelt KR; Miller DK
Curr Drug Abuse Rev; 2010 Sep; 3(3):156-62. PubMed ID: 21054260
[TBL] [Abstract][Full Text] [Related]
20. Randomized, Placebo-Controlled Trial of Targeting Neuroinflammation with Ibudilast to Treat Methamphetamine Use Disorder.
Heinzerling KG; Briones M; Thames AD; Hinkin CH; Zhu T; Wu YN; Shoptaw SJ
J Neuroimmune Pharmacol; 2020 Jun; 15(2):238-248. PubMed ID: 31820289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
